C12N 2810/6027
Ssdna viruses
Official title: ssDNA viruses
C12N2810/6027 (Ssdna viruses) appears on 77 US grants and 115 published applications in this corpus.
Search patents in C12N- Granted patents
- 77
- Published applications
- 115
- Assignees
- 32
- Inventors
- 110
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 3 |
| 2013 | 1 | 9 |
| 2014 | 3 | 4 |
| 2015 | 4 | 8 |
| 2016 | 3 | 9 |
| 2017 | 14 | 11 |
| 2018 | 8 | 16 |
| 2019 | 7 | 11 |
| 2020 | 8 | 6 |
| 2021 | 10 | 11 |
| 2022 | 2 | 7 |
| 2023 | 7 | 3 |
| 2024 | 5 | 7 |
| 2025 | 3 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Capsid-modified, rAAV3 vector compositions and methods of use in gene therapy of human liver cancer10 Mar 2026US 12,570,699 B2University of Florida Research Foundation, Inc.
- Engineered muscle targeting compositions9 Sep 2025US 12,410,447 B2Massachusetts Institute of Technology
- Capsid-modified rAAV vector compositions and methods therefor15 Jul 2025US 12,358,954 B2University of Florida Research Foundation, Inc.
- Synthetic combinatorial AAV3 capsid library7 Jan 2025US 12,188,037 B2University of Florida Research Foundation, Inc.
- AAV vectors targeted to oligodendrocytes3 Sep 2024US 12,076,351 B2The University of North Carolina at Chapel Hill
- Engineered muscle targeting compositions7 May 2026US 2026/0125706 A1Massachusetts Institute of Technology
- Engineered muscle targeting compositions12 Mar 2026US 2026/0071236 A1Massachusetts Institute of Technology
- Engineered muscle targeting compositions13 Feb 2025US 2025/0051800 A1Massachusetts Institute of Technology
- AAV Vectors Targeted to Oligodendrocytes14 Nov 2024US 2024/0374662 A1The University of North Carolina at Chapel Hill
- Methods and compositions for decreasing chronic pain15 Aug 2024US 2024/0269286 A1EOS Neuroscience, Inc.
Most cited
By later US patents
- Recombinant adeno-associated vectors for targeted treatment106US 8,927,514 B2City of Hope · 2015
- Recombinant AAV capsid protein95US 9,585,971 B2California Institute of Technology · 2017
- Recombinant adeno-associated vectors for targeted treatment60US 9,623,120 B2City of Hope · 2017
- AAV vectors with high transduction efficiency and uses thereof for gene therapy57US 9,725,485 B2University of Florida Research Foundation, Inc. · 2017
- Capsid-modified rAAV vectors and methods of use49US 9,775,918 B2University of Florida Research Foundation, Inc. · 2017